SK Minerals & Additives Limited, a manufacturer and supplier of advance additives, nutrients, and chemicals, has reported strong financial performance for the quarter ended March 31, 2026. The company announced an estimated standalone quarterly turnover of Rs. 12708.35 lakhs, marking a significant milestone in its operational growth trajectory.

Financial Performance Overview

The company's revenue performance demonstrates substantial growth across multiple time periods. The quarterly update, submitted under Regulation 30 of SEBI Listing Regulations, reveals impressive year-over-year expansion in the company's business operations.

Year-over-Year Growth Analysis

The most notable aspect of SK Minerals & Additives 's performance is the remarkable year-over-year growth of 50.28%. This growth rate reflects the company's expanding market presence and operational efficiency in the additives, nutrients, and chemicals manufacturing sector.

Quarterly Performance Trends

The Q4FY26 turnover of Rs. 12708.35 lakhs represents a significant increase from the previous quarter's performance of Rs. 8112.68 lakhs in December 2025. This quarter-over-quarter improvement indicates strong business momentum and effective execution of the company's operational strategies.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was signed by Mohit Jindal, Chairman & Managing Director, ensuring proper corporate governance and transparency in financial reporting.

Company Background

SK Minerals & Additives Limited, formerly known as SK Minerals & Additives Private Limited, operates as a manufacturer and supplier in the specialized chemicals sector. The company focuses on advance additives, nutrients, and chemicals, serving various industrial applications with its product portfolio.

SK Minerals & Additives Limited announced significant board changes following resolutions passed by circulation on March 27, 2026. The company's board of directors approved the appointment of a new independent director and reappointment of two existing independent directors for extended terms, as disclosed in their regulatory filing to BSE Limited.

New Director Appointment

The board approved the appointment of Dr. Ashish Mathur as Additional Non-Executive Independent Director, effective March 24, 2026. Dr. Mathur brings extensive expertise to the board with his distinguished academic and industrial background.

Dr. Mathur is a dynamic researcher with proven expertise in developing affordable point-of-care devices, with significant contributions to women's safety, drug abuse detection, and environmental monitoring. He maintains strong collaborations with leading institutions, including IITs and UK-based universities.

Director Reappointments

The board also approved the reappointment of two existing independent directors for second terms of five consecutive years each, subject to shareholder approval.

Ms. Lakshmi Shankarnarayanan Iyer

Mr. Ramit Sikka

Regulatory Compliance

All three directors meet the independence criteria prescribed under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. The appointments comply with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The resolutions were digitally signed by Mohit Jindal, Chairman & Managing Director (DIN: 05351969), on March 27, 2026. These board changes reflect the company's commitment to strengthening its governance structure with experienced professionals from diverse backgrounds.